Cargando…

Observational long-term follow-up study of rapid food oral immunotherapy with omalizumab

BACKGROUND: A number of clinical studies focused on treating a single food allergy through oral immunotherapy (OIT) with adjunctive omalizumab treatment have been published. We previously demonstrated safety and tolerability of a rapid OIT protocol using omalizumab in a phase 1 study to achieve dese...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andorf, Sandra, Manohar, Monali, Dominguez, Tina, Block, Whitney, Tupa, Dana, Kshirsagar, Rohun A., Sampath, Vanitha, Chinthrajah, R. Sharon, Nadeau, Kari C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738812/ https://www.ncbi.nlm.nih.gov/pubmed/29296107 http://dx.doi.org/10.1186/s13223-017-0223-8

Ejemplares similares

Feasibility of sustained response through long-term dosing in food allergy immunotherapy
por: Andorf, Sandra, et al.
Publicado: (2017)

Anti-IgE Treatment with Oral Immunotherapy in Multifood Allergic Participants: Results of a Randomized, Double-blinded Control Trial
por: Andorf, Sandra, et al.
Publicado: (2017)

Oral immunotherapy for peanut allergy: The pro argument
por: Chinthrajah, R. Sharon, et al.
Publicado: (2020)

Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab
por: Bégin, Philippe, et al.
Publicado: (2014)

Shrimp‐allergic patients in a multi‐food oral immunotherapy trial
por: Nguyen, Diem‐Tran I., et al.
Publicado: (2021)

Two year effects of food allergen immunotherapy on quality of life in caregivers of children with food allergies
por: Arasi, Stefania, et al.
Publicado: (2014)

Early intervention of atopic dermatitis as a preventive strategy for progression of food allergy
por: Sweeney, Alyssa, et al.
Publicado: (2021)

Baseline Gastrointestinal Eosinophilia Is Common in Oral Immunotherapy Subjects With IgE-Mediated Peanut Allergy
por: Wright, Benjamin L., et al.
Publicado: (2018)

Early Introduction of Multi-Allergen Mixture for Prevention of Food Allergy: Pilot Study
por: Quake, Antonia Zoe, et al.
Publicado: (2022)

Oral Immunotherapy and Basophil and Mast Cell Reactivity in Food Allergy
por: Paranjape, Anuya, et al.
Publicado: (2020)

CD8(+) T cell differentiation status correlates with the feasibility of sustained unresponsiveness following oral immunotherapy
por: Kaushik, Abhinav, et al.
Publicado: (2022)

Correction: Quake et al. Early Introduction of Multi-Allergen Mixture for Prevention of Food Allergy: Pilot Study. Nutrients 2022, 14, 737
por: Quake, Antonia Zoe, et al.
Publicado: (2022)

A Phase 2 Randomized Controlled Multisite Study Using Omalizumab-facilitated Rapid Desensitization to Test Continued vs Discontinued Dosing in Multifood Allergic Individuals
por: Andorf, Sandra, et al.
Publicado: (2019)

Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange
por: Pennington, Luke F., et al.
Publicado: (2016)

Analysis of a Large Standardized Food Challenge Data Set to Determine Predictors of Positive Outcome Across Multiple Allergens
por: Sindher, Sayantani, et al.
Publicado: (2018)

Corrigendum: Analysis of a Large Standardized Food Challenge Data Set to Determine Predictors of Positive Outcome Across Multiple Allergens
por: Sindher, Sayantani, et al.
Publicado: (2020)

Early peanut introduction wins over the HLA-DQA1*01:02 allele in the interplay between environment and genetics
por: Manohar, Monali, et al.
Publicado: (2022)

The impact of COVID-19 on a national sample of US adults with food allergy
por: Warren, Christopher, et al.
Publicado: (2022)

HLA-associated outcomes in peanut oral immunotherapy trials identify mechanistic and clinical determinants of therapeutic success
por: Kanchan, Kanika, et al.
Publicado: (2022)

Food allergy risks and dining industry – an assessment and a path forward
por: Stankovich, Gabriel A., et al.
Publicado: (2023)

Cross-reactive MHC class I T cell epitopes may dictate heterologous immune responses between respiratory viruses and food allergens
por: Balz, Kathrin, et al.
Publicado: (2023)

Multiple-allergen oral immunotherapy improves quality of life in caregivers of food-allergic pediatric subjects
por: Otani, Iris M, et al.
Publicado: (2014)

Mass cytometry analysis of blood from peanut-sensitized tolerant and clinically allergic infants
por: Tursi, Amanda R., et al.
Publicado: (2022)

Global metabolic profiling to model biological processes of aging in twins
por: Bunning, Bryan J., et al.
Publicado: (2019)

Combination of omalizumab and bee venom immunotherapy: does it work?
por: Yılmaz, İnsu, et al.
Publicado: (2018)

Understanding the impact of the COVID-19 pandemic on physical and mental health
por: Cao, Shu, et al.
Publicado: (2021)

Eliciting Dose and Safety Outcomes From a Large Dataset of Standardized Multiple Food Challenges
por: Purington, Natasha, et al.
Publicado: (2018)

Increased duration of pollen and mold exposure are linked to climate change
por: Paudel, Bibek, et al.
Publicado: (2021)

Safety and feasibility of oral immunotherapy to multiple allergens for food allergy
por: Bégin, Philippe, et al.
Publicado: (2014)

Omalizumab in the prevention of anaphylaxis during immunotherapy: a case report
por: Stelmach, Iwona, et al.
Publicado: (2014)

270 Clinical Experience in Allergic Asthma Patients: Omalizumab with Immunotherapy
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Erratum to: Safety and feasibility of oral immunotherapy to multiple allergens for food allergy
por: Bégin, Philippe, et al.
Publicado: (2016)

Mass cytometry reveals cellular fingerprint associated with IgE+ peanut tolerance and allergy in early life
por: Neeland, Melanie R., et al.
Publicado: (2020)

Dose-dependence of protection from systemic reactions to venom immunotherapy by omalizumab
por: Boni, Elisa, et al.
Publicado: (2016)

Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy
por: Langlois, Alexandra, et al.
Publicado: (2020)

Editorial: Insights Into the Etiology, Prevention, and Treatment of Food Allergy
por: Oyoshi, Michiko, et al.
Publicado: (2020)

Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)
por: Wood, Robert A., et al.
Publicado: (2022)

Rapid clinical improvement of atopic dermatitis in an Omalizumab treated patient
por: Bormioli, Susanna, et al.
Publicado: (2019)

Correction to: Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy
por: Langlois, Alexandra, et al.
Publicado: (2020)

Omalizumab in Children
por: Licari, Amelia, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6rn6a2gj125uu3qjcpkeoef43g